HTA212 Is Protocolized Stopping Lifelong Therapy With Eculizumab With Disease Monitoring and Retreatment for Eligible Atypical Hemolytic Uremic Syndrome (aHUS) Patients Cost-Effective? An Economic Evaluation of the SETS aHUS Trial
Dec 1, 2025, 00:00
10.1016/j.jval.2025.09.1997
https://www.valueinhealthjournal.com/article/S1098-3015(25)04554-1/fulltext
Title :
HTA212 Is Protocolized Stopping Lifelong Therapy With Eculizumab With Disease Monitoring and Retreatment for Eligible Atypical Hemolytic Uremic Syndrome (aHUS) Patients Cost-Effective? An Economic Evaluation of the SETS aHUS Trial
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(25)04554-1&doi=10.1016/j.jval.2025.09.1997
First page :
Section Title :
Open access? :
No
Section Order :
11542